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Abstract
Background: Modern drugs have made large contributions to better health and quality of life. Increasing
proportions of negative side effects due to extensive pharmacological treatment are however observed especially
among elderly patients who have multiple health problems. The aim of our study was to see if there is an
association between medication quality and quality of life.
Methods: 150 patients discharged from hospital. Inclusion criteria were: living in ordinary homes, ≥ 75 years and ≥
5 drugs. Home visits were performed to all, including prescription reviews and calculation of medication
appropriateness index. The patients were divided into three groups depending on index score and followed for 12
months. The validated and recognized EQ-5D and EQ VAS instruments were used to assess quality of life.
Results: A lower medication quality was associated with a lower quality of life. EQ-5D index was statistically
significantly different (declining for each group) among the groups (p = 0.001 at study start, p = 0.001 at 6 months and
p = 0.013 at 12 months) as was EQ VAS (p = 0.026 at study start, p = 0.003 at 6 months and p = 0.007 at 12 months).
Conclusions: This study has shown the validity of the basic principle in prescribing: the more appropriate
medication the better quality of life. Since drug quality is related to the patients’ quality of life, there is immense
reason to continuously evaluate every prescription and treatment. The evaluation and if possible deprescribing
should be done as a process where both the patient and physician are involved.
Background
The ageing process and becoming old is a complex phase
encompassing many perspectives, for example loss of
functions and decreasing autonomy, higher morbidity and
need of care. With an ageing population the real challenge
for the healthcare system is the increasing burden of
chronic diseases and ongoing chronic medication [1].
Modern drugs have made great contributions to health
and quality of life (QoL), though increasing proportions of
negative side effects due to extensive pharmacological
treatment are observed. Prescribing for older people
demands specific knowledge [2,3]. Multi-medication or
polypharmacy, defined as ≥ 5 drugs [4,5] is among the
most obvious signs of risks in drug treatment, resulting
in increased risks for inappropriate drug use and adverse
drug reactions, followed by higher morbidity and hospita-
lization [6-9]. Polypharmacy also include risks of
underutilization of each drug and underprescription of
appropriate drugs [10-12] all possibly affecting QoL. Drug
treatment can be either the facilitator which gives the
opportunities, or the opposite, an intensifier of problems
by occurrence of unacceptable side effects leading to
decreased QoL.
Compared to other age groups there is a greater impact
of health and functional ability on QoL in older ages
[13,14]. If the goal of healthcare is both “to help people
live longer and feel better” [15] there is a need for new
outcome measures including QoL. In the area of medicine
this demands a paradigm shift towards shared decision
and incorporating the patient’s preferences when the cru-
cial factor is QoL [15]. The standardised and non-disease
specific EQ-5D instrument [16] is used to assess the
patient’s health related QoL. Together with their self-rated
QoL via the EQ VAS form, a reliable and valid depiction
of their QoL is obtained.
Assessment of prescription quality and medication
appropriateness demands reliable tools. The medication
appropriateness index (MAI) developed by Hanlon et al
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MAI score is a reliable instrument to evaluate the elderly
patient’s drug therapy [20], to continuously question the
treatment and the lack of follow up, to achieve better and
more appropriate prescribing and most of all to minimize
adverse drug events [3,21,22].
There are currently no studies that have definitively
determined whether various methods designed to reduce
drug-related problems in the elderly affect QoL [23]. The
aim of our study was therefore to see if there is an associa-
tion between medication quality and quality of life. We
also wanted to examine if there is an association between
medication quality and cognitive impairment.
Methods
During the period September 2006 to May 2007, all
patients ready for discharge from the University Hospital
in Örebro, Sweden and fulfilling the criteria were eligible
for the study. Inclusion criteria were: ≥ 75 years, ≥ 5
drugs and living in ordinary homes. Exclusion criteria
were dementia, abuse (all forms of abuse registered in the
patient’s medication record) or malignant disease diag-
nosed before the study start. Moving to a nursing home
during the study also resulted in exclusion. The electro-
nic care planning system (Meddix), used throughout the
County Council and municipalities, made the surveil-
lance of all discharges complete and all patients had the
same opportunity to be included. The study was per-
formed in primary care, since the family physicians are
responsible for the medical care of the elderly after dis-
charge from hospital. The patients in the study were
followed during one year with study end May 2008.
At time of discharge all patients were registered in the
care planning system and a message was sent to the
research centre. If the patient was eligible, a letter con-
cerning the study including informed consent was sent
to the patient.
Within one month after discharge, a home visit was
made (Figure 1). It consisted of questions about satisfaction
and capability of managing the medication and the dosage
regimen/dispensing and screening for cognitive impair-
ment since this is often omitted and is a main issue for the
patients’ capability to handle their medication. Both the
Mini Mental State Examination (MMSE) [24] and clock
drawing test (CDT) were used, as the latter is more sensi-
tive to decline in activities and orientation in daily life
[25,26]. The patients also completed an EQ-5D and EQ
VAS survey. The study nurse asked all patients about their
drug regimen and compliance, to compare with their pre-
scriptions. The “true” drug lists (the combinations of pre-
scriptions from all physicians involved or previously
involved in the patient’s care) were then forwarded to the
research centre. After six months all the patients received a
letter with a new EQ-5D and EQ VAS survey. The study
ended after 12 months with a follow-up home visit includ-
ing EQ-5D, EQ VAS and questions of drug utilization. All
t h eh o m ev i s i t st h r o u g h o u tt h es t u d yw e r ed o n eb yt h e
same study nurse.
To evaluate medication quality the MAI was used. This
index has been developed by Professor Hanlon et al and
was used after personal approval by Professor Hanlon.
The MAI is considered to be the most reliable and valid
comprehensive instrument of today [20]. It consists of
explicit criteria and implicit judgment meaning it permits
standardisation and takes advantage from clinical knowl-
edge and judgment in the evaluation process [19,20]. The
MAI review is based on thorough examinations of the
patients’ medication lists, prescriptions and medical
records. Since all patients in the study had their medical
care provided by the County Council, all data concerning
the medical records and drug lists were available for the
researchers. The medical record for every study patient
was scrutinized systematically, by the same physician and
research assistant throughout the study, according to the
principles of MAI. Every drug was checked in accordance
with the MAI routine on ten items regarding medication
indication, effectiveness, dosage, directions, drug-drug
interactions, drug-disease interactions, practicality,
expense, duplication and duration [17,18]. This renders a
weighted MAI score per drug ranging between 0 (good
quality) and 18 (poor quality). In adherence with the prin-
ciples of appropriate prescribing for elderly [3,21,27,28]
the item of indication was deemed fundamental in our
analysis and scoring of MAI. The assessment of indica-
tions was based on the patients’ medical records.
Every patient’s medical record was scrutinized system-
atically for each drug:
1. Was there an evident diagnose admitting
prescription?
2. If not; were there any notes of a diagnose or
symptom two years before, during or one year after
the study?
3. If no diagnose was evident were there signs of
ongoing follow-up of a specific disease, for example
blood pressure or blood tests like lipids, thyroid hor-
mone and glucose?
I fa n yo ft h e s et h r e ec o n d i t i o n sw e r ef u l f i l l e dt h ed r u g
was considered to have an indication. If the reviewed drug
was determined to be devoid of indication, the grade C
was given which in our analysis resulted in a C in all the
nine following questions. Hence the drug received the
worst (highest) possible MAI score. The total MAI score
for each patient is calculated as the sum of the individual
drug MAIs for that patient.
To measure QoL and functional status the validated
questionnaire EQ-5D was used after approval of the
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ing function in five dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression)
[16,29]. The EQ-5D index was used for an overall estima-
tion of QoL. The preference weights and the calculation
algorithm we used in this study were determined in the
UK using data from the Measurement and Valuation of
Health Survey [30]. EQ VAS was used for self-rating of
current health-related QoL.
The study participants were divided into three equal size
groups, A, B and C. The third of the patients with the low-
est MAI score (measured at study start) and therefore the
“best” medication quality was allocated to group A. Group
B and C represented the thirds with the “middle/centre”
respectively the “worst” medication quality. The groups
were then compared with respect to EQ-5D index and EQ
VAS at the three measuring points (study start, 6 months
and 12 months) and MMSE/CDT at baseline.
The Regional Ethics Committee of Uppsala University
approved the study.
Statistical analyses
The study groups were analysed with respects to EQ-5D
index and EQ VAS measured at study start, 6 months
a n d1 2m o n t h s .J o n c k h e e r e - T e r p s t r at r e n dt e s ta c r o s s
groups was performed. It tests the alternative hypothesis
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Figure 1 Study flow chart.
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direction (that is, if there is a dose-response relationship).
To be able to correct for number of drugs, sex and
age as possible confounding factors, we created a linear
multiple regression model with the EQ-5D index utility
as response variable. The explanatory variables of pri-
mary interest were total MAI score, sex, age and num-
ber of medications. We also performed similar
calculations with EQ VAS as the response variable.
To adjust for comorbidities we used the Charlson
Comorbidity Index [31].
In addition we analysed the different MAI groups with
respects to MMSE and CDT using the Jonckheere-Terpstra
test.
T h ed a t aw e r ea n a l y z e du s i n gt h eS P S Sp r o g r a m ,
version 15.
Results
150 patients were identified for inclusion in the study
(Figure 1). Table 1 shows the characteristics of our study
population. The proportion of patients satisfied with
their drug therapy and patients’ self-rated ability to han-
dle their drug therapy is presented in Table 1. 84% of the
patients in the study claimed to be satisfied with their
drug therapy but only 56% felt able to handle their drug
regimen. 79% of our patients preferred life quality over
long life. Notable is the fact that 32% of the participants
had MMSE < 25 as well as reductions in CDT score indi-
cating possible cognitive impairment. The number of
deaths during the 12 month study period in group A, B
and C were 5 (11%), 7 (15%) respectively 6 (13%). 1, 4
r e s p e c t i v e l y2o ft h e s ep a t i ents died within the first
6 months.
The results from calculating MAI are presented in
Table 2 as are the number of drugs per patient. In addi-
tion to wrong dosages, interaction/duration problems
etc, the fact that a relatively large part of drug regiments
lack indication causes surprisingly high total MAI
scores. Extreme polypharmacy, defined as taking ≥ 10
drugs was common and persistent in all three groups
(Table 2). Some drugs are considered to pose special
risks for the elderly [23]. These are presented in Table 3
together with percent of patients taking the drug and
percent of prescriptions lacking indication.
QoL, measured by EQ-5D, is presented as recom-
mended by the EuroQol group [16] (Table 4).
The results from our statistical analysis are presented
in Table 5 and 6. The Jonckheere-Terpstra test shows
that a lower medication quality is associated with a
lower quality of life. EQ-5D index was statistically signif-
icantly different (declining for each group) among the
groups (p = 0.001 at study start, p = 0.001 at 6 months
and p = 0.013 at 12 months) as was EQ VAS (p = 0.026
at study start, p = 0.003 at 6 months and p = 0.007 at
12 months).
The same analysis was performed after dividing the
study group into two age groups (above and below med-
ian; ≤ 83, ≥ 84 years) and male/female groups to adjust
for age and sex. Even with these small groups the results
remain statistically significant for EQ-5D for 9 out of 12
comparisons (4 groups, 3 different points in time) and
the trend towards lower EQ-5D with lower medication
quality still remains between the groups. For EQ VAS the
results were statistically significant for 7 out of 12 com-
parisons. The same trend with declining EQ VAS with
lower medication quality remains.
When we performed the linear regression with EQ-5D
index as the response variable and MAI groups, age, sex
and number of drugs as explanatory variables we basi-
cally found similar results. The difference in EQ-5D
index between group A and group C was statistically sig-
n i f i c a n ta tt h ef i r s tt w op o i n t si nt i m eb u tn o ta tt h e1 2
month measuring point (p = 0.019 at study start, p =
0.011 at 6 months and p = 0.233 at 12 months). There
was no statistically significant difference between the
middle group and the group with the highest MAI score.
Table 1 Characteristics of the study population
Total
n = 140
Group A
n=4 7
Group B
n=4 7
Group C
n=4 6
Age; mean 83.4 (5.0) 83.3 (4.5) 84.3 (5.4) 82.7 (5.0)
Sex; women (%) 62.1 66.0 53.2 67.4
men (%) 37.9 34.0 46.8 32.6
Mini Mental State Examination (MMSE); 1) median, 2) mean 1) 27 (23 - 28)
2) 25.6 (3.8)
1) 26 (23 - 28)
2) 25.2 (3.5)
1) 27 (23 - 29)
2) 25.3 (4.6)
1) 27 (24 - 29)
2) 26.2 (3.1)
Clock Drawing Test (CDT);
1) median, 2) mean
1) 2.0 (1.0 - 3.0)
2) 1.8 (0.9)
1) 2.0 (1.0 - 3.0)
2) 1.9 (0.9)
1) 2.0 (1.0 - 2.0)
2) 1.7 (0.9)
1) 2.0 (1.8 - 3.0)
2) 1.9 (1.0)
Are satisfied with drug therapy (%) 84.3 85.1 87.2 80.4
Feel able to handle drug therapy (%) 55.7 63.8 44.7 58.7
Prefer life quality before long life (%) 79.3 78.7 78.7 80.4
The values are presented as mean (± SD), median (IQR) or percentage.
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index as the response variable and MAI groups, age, sex
and Charlson Comorbidity Index as explanatory variables
we found that comorbidity did not affect EQ-5D index.
The difference in EQ-5D between MAI group A and
group C was remained statistically significant at the all
three points in time (p = 0.001 at study start, p = 0.002 at
6 months and p = 0.033 at 12 months). There was no sta-
tistically significant difference between the middle group
and the group with the highest MAI score.
For EQ VAS, there was a statistically significant differ-
ence between group A and C at the six and 12 month
measuring points but not at baseline (p = 0.052 at study
start, p = 0.009 at 6 months and p = 0.042 at 12
months). As with EQ-5D index, there was no statistically
significant difference between the middle group and the
group with the highest MAI score.
Number of drugs had a statistically significant impact
on both EQ-5D index and EQ VAS at all points in time.
Sex or age did not affect either EQ-5D index or EQ
VAS.
We also analysed the different MAI groups with respects
to MMSE and CDT using the Jonckheere-Terpstra test. In
our study group we could not find any indication that cog-
nitive impairment is associated with low medication
quality.
Discussion
The main result of our study demonstrates an association
between medication quality and QoL. Through the study
and by using reliable instruments, MAI together with
EQ-5D and EQ VAS, we have been able to visualize the
association between inappropriate medication and low
QoL. We found a remarkable high number of patients
Table 2 Drug treatment and Medication Appropriateness Index
Study start
Total Group A Group B Group C
Number of drugs per patient;
median
10.0 8.0 10.0 12.0
Number of drugs lacking indication per patient; median 3.0 1.0 3.0 6.0
Number of drugs lacking indication per patient; min - max 0 - 15 0 - 2 2 - 4 4 - 15
MAI score
median
54.0 18.0 54.0 108.0
MAI score
mean
61.3 16.0 51.3 117.7
MAI score
min - max
0 - 270 0 - 36 36 - 72 72 - 270
Table 3 Special risk drugs
Percent taking the drug Percent lacking indication
Analgesics (light), ongoing 40.1 36.3
Analgesics (midrange), ongoing 7.5 50.0
Analgesics (strong), ongoing 9.5 47.1
Bulk/laxatives, ongoing 22.4 67.9
Benzodiazepines (short acting), total 10.2 82.4
Benzodiazepines (long acting), total 4.8 66.7
Sleeping tablets, total 44.2 88.1
NSAID, total 5.4 50.0
Neuroleptics, total 3.4 100.0
PPI, totalt 27.9 57.9
Digoxin, total 13.6 35.0
Loop diuretics, total 59.9 18.6
SSRI, total 19 70.4
Other anticholinergics*, total 21.8 70.4
NSAID - Non-Steroidal Anti-Inflammatory Drug
PPI - Proton-Pump Inhibitor
SSRI - Selective Serotonin Reuptake Inhibitor
*Amitriptyline, Clomipramine, Clemastine, Desloratadine, Hydroxyzine, Loratadine, Montelukast and Tolterodine
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importance for the individual as well as the healthcare
system since the vulnerable group of elderly with chronic
health problems and chronic drug treatment is growing.
We find it remarkable that more than four out of five
patients in the study are satisfied with their drug therapy
while only slightly more than half the patients feel able to
handle their drug regimen and the calculation of MAI
shows us that medication quality is overall poor. A possi-
ble reason for the low self-rated capability to handle drug
regimens is the fact that almost one third of the partici-
pants had MMSE < 25 as well as reductions in CDT
score, indicating cognitive impairment. A reason for
patients claiming to be satisfied with their drug therapy
while not being able to handle it could be trust in the
“good doctor” and fear of damaging the doctor-patient
relationship by voicing concerns about their drug therapy
[32].
A ni m p o r t a n ta s p e c ti sw h e t h e rt h eM M S Ea n dC D T
results in our study indicate the ability of the patients to
properly fill in the EQ-5D. According to previous
research the EQ-5D is well suited for evaluating QoL in
a population with cognitive impairment [33].
It is a well established truth that drug treatment and
polypharmacy in the elderly are risk factors for adverse
drug reactions, hospitalization and mortality [22,34,35].
These are factors known to affect QoL. In this study we
set out to see if medication quality could also be associated
to life quality. The reason for this is that we wanted to
study quality of drug treatment from a patient perspective.
With increasing number of elderly who faces the problems
that come with old age, chronic medication and chronic
diseases, the real challenge for the healthcare of tomorrow
is both “to help people live longer and feel better” [15]. To
achieve this, the healthcare professions need to adopt new
outcomes, including QoL. By choosing QoL as an out-
come instead of solely treatment goals per se we wanted
to accomplish more of a patient focus and a movement
towards shared decisions by empowerment of patient
participation.
Polypharmacy is a giant challenge in many ways, but the
objective of our study is appropriateness of the prescrip-
tions in a wide perspective, meaning the burden of drug
treatment for each patient. Appropriateness of medication
is therefore the key word in every part of the discussion,
because if appropriate and needed then the benefits of the
medications are obvious for optimizing QoL. But as
shown here, in many cases there is no indication for the
treatment which is devastating throughout the system and
especially for the patient. Indication as the basic principle
for prescribing is learned by every medical student and is
emphasized in the regulations for physicians and also in
the reimbursement system for drug treatment. A finding is
that there might have been an indication once, but no one
Table 4 Frequency distribution (profile) of the EQ-5D
descriptive system at baseline
Group A
(n = 47)
Group B
(n = 47)
Group C
(n = 46)
Mobility
no problems (%) 13 6 13
some problems (%) 78 85 80
confined to bed (%) 9 9 7
Self-Care
no problems (%) 69 61 60
some problems (%) 24 28 33
unable to (%) 7 11 7
Usual Activities
no problems (%) 48 56 31
some problems (%) 35 20 33
unable to (%) 17 24 36
Pain/Discomfort
none (%) 31 22 22
moderate (%) 54 54 58
extreme (%) 15 24 20
Anxiety/Depression
none (%) 54 46 45
moderate (%) 39 46 53
extreme (%) 7 8 2
The internal loss of follow up was ≤ 3 in all groups.
Table 5 Medication appropriateness and quality of life
Group EQ-5D index
at study start
EQ-5D index
at 6 months
EQ-5D index
at 12 months
Mean Median n= Mean Median n= Mean Median n=
A (lowest MAI score) 0.58 0.73 47 0.59 0.69 34 0.57 0.73 33
B (medium MAI score) 0.51 0.66 44 0.50 0.60 32 0.43 0.62 32
C (highest MAI score) 0.33 0.39 46 0.32 0.41 32 0.37 0.37 34
p = 0.001 p = 0.001 p = 0.013
Statistical analyses were done using Jonckheere-Terpstra trend test.
A higher MAI score equals worse medication quality.
A higher EQ-5D index represents better quality of life (range 0 - 1, though negative values are possible and represents status “worse than death”).
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has defined the time for treatment or the costs. The pre-
sences of interactions remain unnoticed. All these are
important factors for the patients undergoing treatment as
it affects their QoL. For some types of drugs this can seem
as an issue of low significance (for example laxatives and
vitamin pills) but the list of inappropriate drugs in our
patient group also includes pain killers, sleeping pills and
diuretics and in the worst cases anticoagulants and insulin.
In every respect these results show lack of systematic work
in the prescription process. The use of MAI with its expli-
cit and implicit criteria gives an extensive and to some
extent depressive perspective and shows the omission to
fulfill the obligations connected to drug treatment.
To prescribe drugs is important in medical treatment
and demonstrates initiative and action, but good and
appropriate prescribing demands many considerations. It
involves evaluation of symptoms, follow up of effect,
adjustment of dose and monitoring over time as well as
deprescribing when indicated [21,28,36]. Prescribing for
elderly demands special knowledge and close monitoring
[23]. This includes courage to deprescribe and the neces-
sity of avoiding the prescribing cascade [37]. For the
elderly patients who have multiple health problems, the
risks increase as there are often many prescribers with
different specializations involved, focusing on their area
of specialization and with no one taking an overall
responsibility regarding the patient [23].
The patient’s QoL has historically been neglected since
other outcomes are judged more important. Today there
are guidelines for treatment of individual diseases, but
there is a lack of guidelines and goals for treatment of the
elderly with many diseases [38]. In the healthcare system
there are now established incitements and rewards for
following the guidelines for drug treatment (number of
patients with recommended prescriptions) while consid-
ering the patient’s quality of life is subordinate.
Some limitations should be acknowledged. In this study
we have used one measure of QoL, the EQ-5D index.
This is probably the most recognized instrument for
measuring QoL and it is extensively used in international
studies. It is nevertheless possible that a different result
would be obtained with a different measure of QoL. The
same pertain to our chosen measure of medication
quality.
The MAI scoring system does not take into account
that a patient might lack certain drugs that could be ben-
eficiary to them, i.e. underprescription. The possible
reduction in QoL and associated costs resulting from this
underprescription is therefore not taken into account in
this study.
Our study concentrates on the population of elderly
with multiple medications and chronic diseases. Conclu-
sions from this study can therefore not be used to gener-
alize about other parts of the population/community. It
is also a small study. More and bigger studies are needed
to investigate the impact of poor medication quality in
the general population and to confirm the results from
this study.
In this study it was not possible to separate disease
groups from one another since all patients in the study
were multi-diseased and had medical conditions from
several different disease groups. If we would have been
able to separate the different disease groups, and adjust
for these in the analysis, we believe that we might have
found a stronger relationship between medication quality
and QoL. We believe that it is a possibility that poor
medication quality in certain disease groups has a bigger
impact on QoL than others. Further studies are needed
to evaluate if and how poor medication quality in differ-
ent disease groups affect QoL.
The strength of our study is that it is performed in care
as usual. Another strength is the fact that we are describ-
ing a group of people that will keep growing as the base
of the population pyramid in the western world is con-
tracting while the top is expanding. This means that mea-
sures to improve medication quality in the elderly in
o r d e rt oi m p r o v eQ o Lw i l lb eaw a yt oc h a n g eal o tf o r
lots of patients. The fact that we are using the patients’
self stated medication lists as a basis for evaluating their
prescriptions is both a strength and a weakness. By doing
this, we are more likely to capture what medications the
Table 6 Medication appropriateness and quality of life
Group EQ VAS
at study start
EQ VAS
at 6 months
EQ VAS
at 12 months
Mean Median n= Mean Median n= Mean Median n=
A (lowest MAI score) 55.8 50.0 47 61.0 60.0 33 63.2 60.0 32
B (medium MAI score) 51.2 50.0 43 51.7 50.0 32 51.0 50.0 32
C (highest MAI score) 46.2 50.0 46 45.2 50.0 29 51.7 50.0 34
p = 0.026 p = 0.003 p = 0.007
Statistical analyses were done using Jonckheere-Terpstra trend test.
A higher MAI score equals worse medication quality.
A higher EQ VAS represents better self-rated quality of life (range 0 - 100).
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patients’ forgetfulness or possible unwillingness to share
information.
When applying to the Hippocratic Oath, physicians
are taught to do well and not to harm. The hierarchic
structure of healthcare has undergone tremendous
changes but the patient is still in a weak position despite
the ongoing discussion of patient participation and
empowerment. In a world of pharmacological possibili-
ties the debate regarding prescribing ought to be as pro-
minent as ever. Concerning the elderly patient there
must be a crusade finding the breaking point were the
intention to do “well” and not to harm means to depre-
scribe or refrain from prescribing based on shared deci-
sion with the patient to prioritize their QoL.
Conclusion
Drug treatment in the elderly is a huge challenge for
healthcare. Since drug quality is related to the patient’s
quality of life, there is immense reason to continuously
evaluate every prescription and treatment. The evalua-
tion and if possible deprescribing should be done as a
process where both the patient and physician are
involved.
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